Trattamento conservativo e sopravvivenza in pazienti affetti da urotelioma vescicale T1G3. Quando proporlo e quando la cistectomia?
- Bladder Ca guidelines support BCG, mitomycin Tx. Overmyer, Mac // Urology Times;Dec99, Vol. 27 Issue 12, p1
Reports that intravesical bacillus Calmette-Guerin and mitomycin are the preferred therapies following removal of T1 and high-grade Ta bladder cancer tumors. Guidelines from the American Urological Association; Lack of optimal dosages recommended for intravesical therapy and immunotherapy.
- BCG. // Reactions Weekly;11/6/2010, Issue 1326, p10
The article describes the case of a 58-year-old man who developed granulomatous hepatitis while receiving treatment with Bacillus Calmette-GuÃ©rin (BCG) for superficial bladder carcinoma.
- BCG. // Reactions Weekly;1/29/2011, Issue 1336, p10
The article describes the case of a 71-year-old man who presented with systemic granulomatous disease and syndrome of inappropriate antidiuretic hormone (SIADH) while receiving treatment with Bacillus Calmette GuÃ©rin (BCG) for bladder cancer.
- Effective management of superficial bladder cancer. Lamm, Donald L. // Contemporary Urology;Feb2005 Supplement, Vol. 17, p1
Presents information on the use of the bacillus Calmette-Guï¿½rin (BCG) vaccine for the treatment of bladder cancer and carcinoma in situ. History of BCG immunotherapy; Comparison of the effectiveness of BCG with intravesical chemotherapy; Findings of a study of patients with bladder tumors...
- Efficacy and Safety of Bacille Calmette-Guerin Immunotherapy in Superficial Bladder Cancer. Lamm, Donald L. // Clinical Infectious Diseases;9/1/2000 Supplement 4, Vol. 31, pS86
Discusses the use of immunotherapy with intravesical bacille Calmette-Guerin (BCG) vaccines as an effective alternative approach to chemotherapy in the management of superficial bladder cancer. Expected long-term reduction in tumor recurrence, tumor progression and cancer mortality; Decrease in...
- Mechanisms of Action of Intravesical Bacile Calmette-Guerin: Loca Immune Mechanisms. Prescott, Stephen; Jackson, Andrew M.; Hawkyard, Simon J.; Alexandroff, Anton B.; James, Keith // Clinical Infectious Diseases;9/1/2000 Supplement 4, Vol. 31, pS91
Discusses how Bacille Calmette-Guerin (BCG) vaccination is associated with the development of antituberculosis immunity but not necessarily with antitumor immunity. Local immune response to mycobacteria; Animal studies showing that an intact host immune system is required for the antitumor...
- In Vitro Generation of Bacillus Calmette-Guerin-Activated Killer Cells. Brandau, S.; Bohle, A.; Thanhauser, A.; Ernst, M.; Mattern, T.; Ulmer, A.J.; Flad, H.-D. // Clinical Infectious Diseases;9/1/2000 Supplement 4, Vol. 31, pS94
Describes the induction of bacillus Calmette-Guerin (BCG)-activated killer (BAK) cells, which effectively lyse bladder tumor cells. Study of the immunostimulatory effects of BCG; Monoclonal antibodies that abolished BCG-mediated cytotoxicity; Beneficial effect of BCG on maintenance of the...
- Genetics may provide clues to BCG non-response. Overmyer, Mac // Urology Times;Jul2000, Vol. 28 Issue 7, p19
Reports on the study conducted by researchers from the Hotel-Dieu de Quebec which revealed resistance to BCG immunotherapy among patients with bladder cancer. Role of the human natural resistance-associated macrophage protein 1 in the dampening or elimination of immunologic response; Allotype...
- Spectrum of Bacille Calmette-Guerin (BCG) Infection after Intravesical BCG Immunotherapy. Gonzalez, Omar Y.; Musher, Daniel M.; Brar, Indira; Furgeson, Seth; Boktour, Maha R.; Septimus, Edward J.; Hamil, Richard J.; Graviss, Edward A. // Clinical Infectious Diseases;1/15/2003, Vol. 36 Issue 2, p140
Intravesical instillation of bacille Calmette-Guï¿½rin (BCG) effectively treats transitional cell carcinoma of the bladder. Occasionally, BCG infection complicates such treatment. In some patients, infection appears early (within 3 months after instillation) and is characterized by...